{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:08:31Z","timestamp":1790230111000,"version":"4.1.0"},"reference-count":251,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.00888","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:17:05Z","timestamp":1540282625000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":206,"title":["Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis"],"prefix":"10.3389","volume":"9","author":[{"given":"Nadja","family":"Borisow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"B1","first-page":"1033","article-title":"My\u00e9lite aigu\u00eb compliqu\u00e9e de n\u00e9vrite optique","volume":"8","author":"Devic","year":"1894","journal-title":"Bull M\u00e9dicale"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1742-2094-10-8","article-title":"The history of neuromyelitis optica","volume":"10","author":"Jarius","year":"2013","journal-title":"J Neuroinflammation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0035-1567186","article-title":"[Neuromyelitis optica]","volume":"85","author":"Pache","year":"2017","journal-title":"Fortschr Neurol Psychiatr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin Proc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1212\/NXI.0000000000000204","article-title":"Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis","volume":"3","author":"Metz","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jocn.2010.12.052","article-title":"Prominent brainstem symptoms\/signs in patients with neuromyelitis optica in a Taiwanese population","volume":"18","author":"Wang","year":"2011","journal-title":"J Clin Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1212\/NXI.0000000000000286","article-title":"Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder","volume":"3","author":"Chavarro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nrneurol.2017.117","article-title":"Fatigue as a symptom or comorbidity of neurological diseases","volume":"13","author":"Penner","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1212\/NXI.0000000000000094","article-title":"Sleep abnormality in neuromyelitis optica spectrum disorder","volume":"2","author":"Song","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2055217318796684","DOI":"10.1177\/2055217318796684","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1212\/NXI.0000000000000447","article-title":"Short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms in NMOSD","volume":"5","author":"Mizuno","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1212\/NXI.0000000000000351","article-title":"Spontaneous remission lasting more than a decade in untreated AQP4 antibody-positive NMOSD","volume":"4","author":"Pandit","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: a multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: A review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00415-015-7766-8","article-title":"Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75","volume":"262","author":"Krumbholz","year":"2015","journal-title":"J Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1177\/1352458516671203","article-title":"Influence of female sex and fertile age on neuromyelitis optica spectrum disorders","volume":"23","author":"Borisow","year":"2017","journal-title":"Mult Scler."},{"key":"B23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","article-title":"Neuromyelitis optica: effect of gender","volume":"286","author":"Wingerchuk","year":"2009","journal-title":"J Neurol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/ene.12058","article-title":"Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients","volume":"20","author":"Kiyat-Atamer","year":"2013","journal-title":"Eur J Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain J Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1212\/NXI.0000000000000335","article-title":"ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports","volume":"4","author":"K\u00f6rtv\u00e9lyessy","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2055217316675634","DOI":"10.1177\/2055217316675634","article-title":"Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India","volume":"2","author":"Pandit","year":"2016","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B42","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1212\/WNL.0000000000002825","article-title":"Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1586\/14737175.2015.1126510","article-title":"Diagnosis and therapy of acute disseminated encephalomyelitis and its variants","volume":"16","author":"Berzero","year":"2016","journal-title":"Expert Rev Neurother."},{"key":"B44","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1046\/j.1471-4159.1998.71041742.x","article-title":"A molecular model of myelin oligodendrocyte glycoprotein","volume":"71","author":"Hjelmstr\u00f6m","year":"1998","journal-title":"J Neurochem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.brainresrev.2004.01.003","article-title":"Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function","volume":"45","author":"Vourc'h","year":"2004","journal-title":"Brain Res Brain Res Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"MOG antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1212\/NXI.0000000000000400","article-title":"Muscle damage in patients with neuromyelitis optica spectrum disorder","volume":"4","author":"Chen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody","volume":"256","author":"Baba","year":"2009","journal-title":"J Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/NXI.0000000000000412","article-title":"Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis","volume":"5","author":"Pandit","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000503","article-title":"MOG antibodies in combined central and peripheral demyelination syndromes","author":"Vazquez Do Campo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u201cpattern II multiple sclerosis\u201d and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler."},{"key":"B59","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","article-title":"Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss","volume":"123","author":"Ratelade","year":"2012","journal-title":"Acta Neuropathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain J Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e79649","DOI":"10.1371\/journal.pone.0079649","article-title":"Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8","volume":"8","author":"Aboul-Enein","year":"2013","journal-title":"PloS ONE"},{"key":"B64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jneuroim.2016.11.010","article-title":"The clinical characteristics of AQP4 antibody positive NMO\/SD in a large cohort of Chinese Han patients","volume":"302","author":"ZhangBao","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1177\/1352458517734070","article-title":"A population-based prospective study of optic neuritis","volume":"23","author":"Soelberg","year":"2017","journal-title":"Mult Scler."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13004","article-title":"Optical coherence tomography in acute optic neuritis: A population-based study","author":"Soelberg","year":"2018","journal-title":"Acta Neurol Scand."},{"key":"B69","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J Neurol Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scler."},{"key":"B74","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur J Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2055217318787829","DOI":"10.1177\/2055217318787829","article-title":"MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"B76","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neuroimmunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat Clin Pract Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1212\/NXI.0000000000000386","article-title":"Frequencies of neuronal autoantibodies in healthy controls: Estimation of disease specificity","volume":"4","author":"Lang","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jamaneurol.2014.1581","article-title":"Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis","volume":"71","author":"Pittock","year":"2014","journal-title":"JAMA Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/WNL.0000000000001749","article-title":"Pushing the boundaries of neuromyelitis optica: does antibody make the disease?","volume":"85","author":"Kister","year":"2015","journal-title":"Neurology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/1352458510389220","article-title":"Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children","volume":"17","author":"Lalive","year":"2011","journal-title":"Mult Scler."},{"key":"B87","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0165-5728(91)90014-X","article-title":"Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls","volume":"31","author":"Xiao","year":"1991","journal-title":"J Neuroimmunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/5532","article-title":"Identification of autoantibodies associated with myelin damage in multiple sclerosis","volume":"5","author":"Genain","year":"1999","journal-title":"Nat Med."},{"key":"B89","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/122.11.2047","article-title":"Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study","volume":"122","author":"Reindl","year":"1999","journal-title":"Brain J Neurol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/archneurol.2010.197","article-title":"Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis","volume":"67","author":"Klawiter","year":"2010","journal-title":"Arch Neurol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0304-3940(01)01949-8","article-title":"Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica","volume":"307","author":"Haase","year":"2001","journal-title":"Neurosci Lett."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2017.08.005","article-title":"Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: a multicenter cohort study","volume":"17","author":"Kessler","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","author":"Mealy","year":"2017","journal-title":"Mult Scler."},{"key":"B97","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","article-title":"MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflamm."},{"key":"B98","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J Neuroinflamm."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B100","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity"},{"key":"B102","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10067-010-1502-7","article-title":"Association of neuromyelitis optic (NMO) with autoimmune disorders: report of two cases and review of the literature","volume":"29","author":"Sergio","year":"2010","journal-title":"Clin Rheumatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/1352458511403958","article-title":"Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders","volume":"17","author":"Jarius","year":"2011","journal-title":"Mult Scler."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/1352458511431728","article-title":"Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature","volume":"18","author":"Jarius","year":"2012","journal-title":"Mult Scler."},{"key":"B107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2009.08.040","article-title":"Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis","volume":"287","author":"Uzawa","year":"2009","journal-title":"J Neurol Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.msard.2017.12.012","article-title":"Paraneoplastic neuromyelitis optica spectrum disorder: a single center cohort description with two cases of histological validation","volume":"20","author":"Beauchemin","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B109","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/NXI.0000000000000252","article-title":"Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer","volume":"3","author":"Soelberg","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1212\/NXI.0000000000000482","article-title":"Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4","volume":"5","author":"Sudo","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s00415-012-6677-1","article-title":"Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"259","author":"Jarius","year":"2012","journal-title":"J Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.24582","article-title":"Discriminating long myelitis of neuromyelitis optica from sarcoidosis","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jocn.2012.09.030","article-title":"Sarcoidosis associated with neuromyelitis optica","volume":"20","author":"Sawaya","year":"2013","journal-title":"J Clin Neurosci."},{"key":"B115","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics","volume":"14","author":"Geraldes","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1352458515591069","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging","volume":"22","author":"Pekcevik","year":"2016","journal-title":"Mult Scler."},{"key":"B119","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458513495581","article-title":"\u201cBright spotty lesions\u201d on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis","volume":"20","author":"Yonezu","year":"2014","journal-title":"Mult Scler."},{"key":"B120","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1212\/WNL.0b013e318297ef07","article-title":"Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patient","volume":"81","author":"Asgari","year":"2013","journal-title":"Neurology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ana.24184","article-title":"Specific pattern of gadolinium enhancement in spondylotic myelopathy","volume":"76","author":"Flanagan","year":"2014","journal-title":"Ann Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1212\/NXI.0000000000000333","article-title":"Longitudinally extensive myelitis in MS mimicking neuromyelitis optica","volume":"4","author":"Whittam","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B124","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann Neurol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1212\/NXI.0000000000000481","article-title":"GFAP\u03b1 IgG-associated encephalitis upon daclizumab treatment of MS","volume":"5","author":"Luessi","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B127","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/1352458506070725","article-title":"Brain magnetic resonance imaging findings in relapsing neuromyelitis optica","volume":"13","author":"Cabrera-G\u00f3mez","year":"2007","journal-title":"Mult Scler."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"20170690","DOI":"10.1259\/bjr.20170690","article-title":"Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review","volume":"91","author":"Wang","year":"2018","journal-title":"Br J Radiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.msard.2017.11.004","article-title":"Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients","volume":"19","author":"Carnero Contentti","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B132","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.msard.2017.02.003","article-title":"Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody","volume":"13","author":"Fan","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1212\/NXI.0000000000000343","article-title":"Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder","volume":"4","author":"Asgari","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B134","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler."},{"key":"B135","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","article-title":"Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica","volume":"293","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain J Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jurynczyk","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1212\/WNL.0000000000002655","article-title":"Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder","volume":"86","author":"Hyun","year":"2016","journal-title":"Neurology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaneurol.2015.0248","article-title":"Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder","volume":"72","author":"Kremer","year":"2015","journal-title":"JAMA Neurol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1212\/NXI.0000000000000229","article-title":"Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD","volume":"3","author":"Finke","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B141","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00330-016-4282-x","article-title":"Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study","volume":"26","author":"Pache","year":"2016","journal-title":"Eur Radiol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1212\/NXI.0000000000000449","article-title":"Multicenter reliability of semiautomatic retinal layer segmentation using OCT","volume":"5","author":"Oberwahrenbrock","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B143","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","article-title":"Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy","volume":"9","author":"Oertel","year":"2018","journal-title":"EPMA J."},{"key":"B144","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2147\/DNND.S73506","article-title":"Optical coherence tomography for retinal imaging in multiple sclerosis","volume":"2014","author":"Zimmermann","year":"2014","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00115-017-0444-6","article-title":"[Optical coherence tomography in neuromyelitis optica spectrum disorders]","volume":"88","author":"Oertel","year":"2017","journal-title":"Nervenarzt"},{"key":"B146","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1212\/NXI.0000000000000492","article-title":"Temporal visual resolution and disease severity in MS","volume":"5","author":"Ayadi","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B147","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1212\/NXI.0000000000000427","article-title":"Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS","volume":"5","author":"You","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1212\/NXI.0000000000000356","article-title":"Optical coherence tomography and visual evoked potentials in pediatric MS","volume":"4","author":"Waldman","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B149","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler."},{"key":"B150","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","article-title":"The investigation of acute optic neuritis: a review and proposed protocol","volume":"10","author":"Petzold","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jamaneurol.2017.3890","article-title":"Association of visual impairment in neuromyelitis optica spectrum disorder with visual network reorganization","volume":"75","author":"Finke","year":"2018","journal-title":"JAMA Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e66151","DOI":"10.1371\/journal.pone.0066151","article-title":"Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis","volume":"8","author":"Schneider","year":"2013","journal-title":"PloS ONE"},{"key":"B154","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J Neurol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1177\/1352458513476562","article-title":"Longitudinal follow-up of vision in a neuromyelitis optica cohort","volume":"19","author":"Bouyon","year":"2013","journal-title":"Mult Scler."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1212\/NXI.0000000000000338","article-title":"Contribution of blood vessels to retinal nerve fiber layer thickness in NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B158","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamaneurol.2013.1832","article-title":"Microcystic inner nuclear layer abnormalities and neuromyelitis optica","volume":"70","author":"Gelfand","year":"2013","journal-title":"JAMA Neurol."},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","author":"Jelcic","year":"2018","journal-title":"J Neuro-Ophthalmol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","article-title":"Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica","volume":"313","author":"Akaishi","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"e0170847","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PloS ONE"},{"key":"B162","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1756285616655264","article-title":"Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders","volume":"9","author":"Martinez-Lapiscina","year":"2016","journal-title":"Ther Adv Neurol Disord."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1212\/NXI.0000000000000347","article-title":"Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?","volume":"4","author":"Yamamura","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B164","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1212\/NXI.0000000000000345","article-title":"Precision in neuroimmunology","volume":"4","author":"Dalmau","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J Neurol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody-seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study","author":"Oertel","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch Ophthalmol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.msard.2018.04.006","article-title":"Frequent retinal ganglion cell damage after acute optic neuritis","volume":"22","author":"Brandt","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B171","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult Scler."},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates","author":"Sep\u00falveda","year":"2017","journal-title":"Mult Scler."},{"key":"B173","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler."},{"key":"B174","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","article-title":"Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature","volume":"13","author":"Aungsumart","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"B175","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1756285616646332","article-title":"Immunoadsorption in patients with neuromyelitis optica spectrum disorder","volume":"9","author":"Faissner","year":"2016","journal-title":"Ther Adv Neurol Disord."},{"key":"B176","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B177","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"S612","DOI":"10.4103\/2230-8210.123548","article-title":"Management issues with exogenous steroid therapy","volume":"17","author":"Patt","year":"2013","journal-title":"Indian J Endocrinol Metab."},{"key":"B181","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B182","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jocn.2015.01.028","article-title":"Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica","volume":"22","author":"Qiu","year":"2015","journal-title":"J Clin Neurosci."},{"key":"B184","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol Belg."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler."},{"key":"B186","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"B187","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B188","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurother J Am Soc Exp Neurother."},{"key":"B189","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B190","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","article-title":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","volume":"372","author":"Evangelopoulos","year":"2017","journal-title":"J Neurol Sci."},{"key":"B191","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J Neurol Sci."},{"key":"B192","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev Neurol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11481-015-9646-5","article-title":"Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID)","volume":"11","author":"Rommer","year":"2016","journal-title":"J Neuroimmune Pharmacol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"B196","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J Neurol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler."},{"key":"B198","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J Neurol Sci."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J Neurol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1212\/NXI.0000000000000188","article-title":"Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder","volume":"3","author":"Nosadini","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaneurol.2016.5933","article-title":"Rituximab in neuromyelitis optica spectrum disorders: why not as first-line therapy","volume":"74","author":"Kim","year":"2017","journal-title":"JAMA Neurol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B206","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B207","first-page":"90","article-title":"Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)","author":"Whittam","year":"2018","journal-title":"Neurology"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/WNF.0000000000000131","article-title":"The Efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China","volume":"39","author":"Chen","year":"2016","journal-title":"Clin Neuropharmacol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci."},{"key":"B212","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2015.03.021","article-title":"Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica","volume":"282","author":"Viswanathan","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler."},{"key":"B215","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B216","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B217","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2377-14-51","article-title":"Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate","volume":"14","author":"Ramanathan","year":"2014","journal-title":"BMC Neurol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00415-015-7991-1","article-title":"Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study","volume":"263","author":"Ayzenberg","year":"2016","journal-title":"J Neurol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1212\/NXI.0000000000000208","article-title":"Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab","volume":"3","author":"Kowarik","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B223","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B224","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1212\/NXI.0000000000000038","article-title":"Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?","volume":"1","author":"Fujihara","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B225","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00415-015-7925-y","article-title":"Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series","volume":"263","author":"Azzopardi","year":"2016","journal-title":"J Neurol."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/1352458517703803","article-title":"Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?","volume":"23","author":"Kira","year":"2017","journal-title":"Mult Scler."},{"key":"B227","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.msard.2016.03.004","article-title":"Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder","volume":"7","author":"Yoshii","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B228","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1177\/1352458517694086","article-title":"Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Yamout","year":"2017","journal-title":"Mult Scler."},{"key":"B230","doi-asserted-by":"publisher","first-page":"e363","DOI":"10.1212\/NXI.0000000000000363","article-title":"Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS","volume":"4","author":"Gahlen","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B231","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B232","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1756285611433318","article-title":"Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany","volume":"5","author":"Stroet","year":"2012","journal-title":"Ther Adv Neurol Disord."},{"key":"B234","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1212\/WNL.0b013e3181b878f6","article-title":"Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment","volume":"73","author":"D\u00f6rr","year":"2009","journal-title":"Neurology"},{"key":"B235","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/jnnp.2006.091033","article-title":"Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis","volume":"78","author":"Paul","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B236","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/archneurol.2012.545","article-title":"Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients","volume":"69","author":"Bichuetti","year":"2012","journal-title":"Arch Neurol."},{"key":"B237","unstructured":"A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders - Full Text View - ClinicalTrials.gov"},{"key":"B238","doi-asserted-by":"publisher","first-page":"E107","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B Cell-Depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies","volume":"5","author":"Chen","year":"2016","journal-title":"J Clin Med."},{"key":"B239","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","article-title":"Placebo-controlled study in neuromyelitis optica-Ethical and design considerations","volume":"22","author":"Cree","year":"2016","journal-title":"Mult Scler."},{"key":"B240","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1474-4422(13)70089-9","article-title":"Hope for a rare disease: eculizumab in neuromyelitis optica","volume":"12","author":"Paul","year":"2013","journal-title":"Lancet Neurol."},{"key":"B242","unstructured":"An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients - Full Text View - ClinicalTrials.gov"},{"key":"B243","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"key":"B244","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.msard.2017.12.002","article-title":"Treatment for paraneoplastic neuromyelitis optica spectrum disorder (NMOsd): Probable effects of tocilizumab for both cancer and NMOsd","volume":"20","author":"Tanaka","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"B246","unstructured":"Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders - Full Text View - ClinicalTrials.gov"},{"key":"B247","unstructured":"Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD - Full Text View - ClinicalTrials.gov"},{"key":"B248","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B249","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: Part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B250","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","article-title":"Investigational drugs in development to prevent neuromyelitis optica relapses","volume":"27","author":"Paul","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B251","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1212\/NXI.0000000000000328","article-title":"Ruxolitinib treatment in a patient with neuromyelitis optica: a case report","volume":"4","author":"Hodecker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:17:21Z","timestamp":1540282641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2018.00888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":251,"alternative-id":["10.3389\/fneur.2018.00888"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.00888","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"article-number":"888"}}